NCT06806293: An ongoing trial by AbbVie
This trial is ongoing. It must report results 9 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06806293 |
|---|---|
| Title | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 10, 2025 |
| Completion date | June 29, 2026 |
| Required reporting date | June 29, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Sept. 11, 2026 |
| Days late | None |